Boehringer Ingelheim, Envisagenics Signed $1 Billion Deal
The pharmaceutical company will utilize AI-driven transcriptomics to identify new cancer targets.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you believe large-scale pharmaceutical partnerships are an effective way to develop new medical treatments?
Boehringer Ingelheim and New York-based Envisagenics have entered a $1 billion multi-year partnership. This collaboration integrates the SpliceCore AI platform into the German firm's oncology research pipeline.
Why it matters
Boehringer Ingelheim intends to use the platform to validate tumor-specific targets for antibody-drug conjugates and T-cell engagers. Meanwhile, Envisagenics will leverage the capital to push its own internal CNS drug candidates into clinical trials.
The SpliceCore platform screens more than 14 million splicing events to distinguish cancer cells from healthy tissue. This AI-driven technology was developed using the same foundational research as the drug Spinraza.
The players
Boehringer Ingelheim
A German pharmaceutical corporation focused on human and animal health that is currently scaling its AI-driven oncology discovery stack.
Envisagenics
A New York-based biotechnology firm specializing in RNA splicing research and transcriptomic analysis for drug discovery.
The details
The SpliceCore platform employs large-scale transcriptomics—the study of the complete set of RNA transcripts in a cell—to identify tumor-specific markers. By analyzing alternative RNA splicing, the system detects how cancer cells deviate from healthy tissue at a molecular level. This mechanism allows researchers to differentiate malignancy from normal biological function, creating precise targets for therapeutic development.
Timeline
June 2025: Boehringer Ingelheim signed an AI partnership with Immunai.
September 22, 2026: Boehringer Ingelheim and Envisagenics announced their $1 billion collaboration.
The Tech Race
This deal extends a trend of major pharmaceutical companies integrating AI-based RNA analysis into their target identification workflows. The platform leverages research lineage shared with Spinraza to compete for precision in oncology drug development.
This agreement provides the financial runway for Envisagenics to accelerate its internal drug development pipeline. Industry researchers should monitor for upcoming clinical data on the company's lead ALS candidate, ENV-375.
The takeaway
This partnership marks a significant increase in capital committed to AI-assisted RNA splicing research. Watch for future clinical trial filings regarding ENV-375 as an indicator of the platform's potential for non-oncology therapeutic development.
What happens next
Envisagenics plans to advance its lead internal preclinical ALS asset, ENV-375, into clinical trials.
Further reading
For broader trends in computational drug discovery, explore our latest coverage in Biotech.
Live Poll
Do you believe large-scale pharmaceutical partnerships are an effective way to develop new medical treatments?
